1. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study. Saito Y, Hamamoto Y, Hirata K, Yamasaki M, Watanabe M, Abe T, Tsubosa Y, Hamai Y, Murakami K, Bamba T, Yoshii T, Tsuda M, Watanabe M, Ueno M, Kitagawa Y.BMC Cancer. 2023 Mar 28;23(1):283. doi: 10.1186/s12885-023-10710-y. 

2. Prognostic impact of perioperative change in serum p53 antibody titers in esophageal squamous cell carcinoma. Haneda R, Mayanagi S, Inoue M, Ishii K, Morita Y, Kikuchi H, Hiramatsu Y, Takeuchi H, Tsubosa Y. Esophagus. 2023 Oct;20(4):669-678. doi: 10.1007/s10388-023-01013-z. Epub 2023 May 22.

3. Ramelteon and suvorexant for postoperative delirium in elderly patients with esophageal cancer. Mayanagi S, Haneda R, Inoue M, Ishii K, Tsubosa Y. Esophagus. 2023 Oct;20(4):635-642. doi: 10.1007/s10388-023-01019-7. Epub 2023 Aug 10.

4. A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904). Sasaki K, Nomura M, Kato K, Sakanaka K, Ito Y, Kadota T, Machida R, Kataoka T, Minashi K, Tsubosa Y, Kajiwara T, Fukuda H, Takeuchi H, Mizowaki T, Nishimura Y, Kitagawa Y. Jpn J Clin Oncol. 2024 Jan 7;54(1):103-107. doi: 10.1093/jjco/hyad137.

5. Clinical Significance of Albumin-Bilirubin Grade in Thoracic Esophageal Squamous Cell Carcinoma. Kitahama T, Ishii K, Haneda R, Inoue M, Mayanagi S, Tsubosa Y. J Surg Res. 2024 Mar;295:673-682. doi: 10.1016/j.jss.2023.08.056. Epub 2023 Dec 20.